[ NASDAQ: MEIP ] Cowen and Company Health Care Conference March 2015
|
|
- Rudolf Fox
- 5 years ago
- Views:
Transcription
1 [ NASDAQ: MEIP ] Cowen and Company Health Care Conference March 2015
2 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or results may differ materially from those projected in any of such statements. Additional information concerning factors that may cause actual events or results to differ from those projected is contained in MEI Pharma s most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other subsequent filings with the SEC. 2
3 MEI Pharma (Nasdaq: MEIP) San Diego-based oncology company focused on the clinical development of three wholly owned drug candidates Pracinostat: Oral HDAC inhibitor with clinical activity in MDS and AML o Significant activity in combination with azacitidine in elderly AML 3 o Data from randomized Phase II MDS study expected in March 2015 ME-344: Novel mitochondrial inhibitor with single-agent activity o Data from Phase Ib study expected in 2015 PWT143: PI3K delta inhibitor with compelling pre-clinical activity o On track to enter clinic in 1H 2015 Strong intellectual property protection extending past 2028 in US Management team with proven oncology drug development experience
4 Management Team EXECUTIVE MANAGEMENT Daniel Gold, PhD President & Chief Executive Officer Former Chief Scientific Officer & Founder, Favrille Robert Mass, MD Chief Medical Officer Former Head of Medical Affairs, BioOncology, Genentech Thomas Zech Chief Financial Officer Former Chief Financial Officer, Pacira Pharmaceuticals David Urso, JD SVP, Corporate Development & General Counsel Former Principal, Forward Ventures / COO, Tioga Pharmaceuticals Karen Potts, PhD SVP, Regulatory Affairs Former SVP of Regulatory Affairs, Trius Therapeutics BOARD OF DIRECTORS Christine White, MD (Lead Director) Former Head of Global Medical Affairs, Biogen Idec Charles Baltic, JD Co-Head of Healthcare, Needham & Co. Leah Cann, MBA Two-time Wall Street Journal All-Star Analyst Kevan Clemens, PhD Former Head of Global Oncology, Roche Nick Glover, PhD Former President & CEO, YM BioSciences Daniel Gold, PhD President & CEO, MEI Pharma Thomas Reynolds, MD, PhD Former Chief Medical Officer, Seattle Genetics William Rueckert Former Chairman, Novogen Limited 4
5 SIGNALING PROGRAM CANCER METABOLISM PROGRAM EPIGENETICS PROGRAM Clinical Development Pipeline DRUG CANDIDATE INDICATION / COMBINATION PRE-CLINICAL PHASE I PHASE II PHASE III Myelodysplastic Syndrome Front Line, Int-2 & High-Risk Azacitidine (Vidaza ) Pracinostat HDAC Inhibitor ME-344 Mitochondrial Inhibitor Acute Myeloid Leukemia Front Line, Elderly Azacitidine (Vidaza ) Myelodysplastic Syndrome Refractory to HMA Azacitidine (Vidaza ) or Decitabine (Dacogen ) Myelofibrosis Front Line & Relapsed/Refractory Ruxolitinib (Jakafi ) Small Cell Lung Cancer Advanced or Metastatic Topotecan (Hycamtin ) Ovarian Cancer Advanced or Metastatic Topotecan (Hycamtin ) PWT143 PI3K Delta Inhibitor Hematologic Cancers 5
6 Pracinostat: A Differentiated HDAC Inhibitor Potent inhibitor of Class I, II and IV HDAC isoenzymes Well tolerated Tested in 300+ adult and pediatric patients in multiple hematologic and solid tumor Phase I and Phase II clinic trials Manageable side effects consistent with drugs of this class include fatigue and gastrointestinal discomfort Best-in-class pharmacokinetic profile, broadly active Generation of SB991, the major and highly active in vivo metabolite of Pracinostat, yields in vivo combined on target IC 50 activity for HDAC1 predicted to be >24 hours 6
7 Pracinostat: Clinical Activity in MDS Evidence of activity in combination with azacitidine in intermediate-2 or high-risk myelodysplastic syndrome (MDS) 1 90% (9/10) CR/CRp rate in pilot study o CR = 60% (6/10) Rapid complete bone marrow responses observed o o 50% (5/10) achieved complete cytogenetic bone marrow response 50% (5/10) went on to bone marrow transplantation 7 1 Quintás-Cardama et al. Very high rates of clinical and cytogenetic response with the combination of the histone deacetylase inhibitor Pracinostat (sb939) and 5-azacitidine in high-risk myelodysplastic syndrome ASH Annual Meeting
8 MDS Pilot Study Three Years Later 8
9 Phase II Study in Front Line MDS (MEI-003) Intermediate Risk-2 or High Risk MDS Patients Previously Untreated w/ HMA Pracinostat + Azacitidine Placebo + Azacitidine Primary Endpoint: CR 9 Secondary endpoints: overall response rate, hematologic improvement, clinical benefit rate, duration of response, progression-free survival, rate of leukemic transformation, overall survival, safety & tolerability 102 evaluable patients enrolled, one-to-one randomization 24 sites in the U.S. Expect to unblind study and report top-line data in March 2015
10 Phase II Study in HMA Refractory MDS (MEI-005) Reached clinical milestone in December 2014 Three responses (one PR and two marrow CRs) out of first 28 patients who received Pracinostat + HMA (azacitidine or decitabine) after progressing on the same HMA alone Exceeded the pre-specified response rate (two out of 29) for expansion of study enrollment Combination of Pracinostat + azacitidine or decitabine generally welltolerated in the study with no unexpected toxicities Most common treatment-emergent adverse events: anemia, fatigue and gastrointestinal disorders Study enrollment complete (39 patients); continue to follow patients for response and survival One additional marrow CR to date 10
11 Pracinostat: Clinical Activity in AML Evidence of single-agent activity in elderly AML 1 14% (2/14) CR rate in Phase I dose-escalation study Significant activity in combination with azacitidine in elderly AML 2 50 patients enrolled in Phase II study at 15 sites in the U.S. Interim data from 33 evaluable patients reported at ASH o Primary endpoint: CR/CRi/MLFS rate = 45% (15/33) as of Dec 2014 o No patient who achieved a clinical response had progressed 11 1 Garcia Manero et al. Phase 1 Study of the Oral Deacetylase Inhibitor, SB939, in Patients with Advanced Hematologic Malignancies ASH Annual Meeting 2 Garcia-Manero et al. Pracinostat in Combination with Azacitidine Produces a High Rate and Rapid Onset of Disease Remission in Patients with Previously Untreated Acute Myeloid Leukemia ASH Annual Meeting
12 1 st Line Elderly AML Patients (N=33) Phase II Study in Front Line AML (MEI-004) Duration on Study and Response ASH 2014 Response Based on Clinical Review of Efficacy Data CR CRi MLFS PR/PRi Stable Disease Progressive Disease Clinical Benefit AE/Withdrew No Clinical Benefit AE/Withdrew Time to 1 st BM Assessment for Responders Remains on treatment Days on Study 12
13 1 st Line Elderly AML Patients (N=33) Phase II Study in Front Line AML (MEI-004) Duration on Study and Response Today Response Based on Clinical Review of Efficacy Data * CR CRi * * * * MLFS PR/PRi Stable Disease Progressive Disease Clinical Benefit AE/Withdrew No Clinical Benefit AE/Withdrew Time to 1 st BM Assessment for Responders Remains on treatment Months on Study 13 * Patients with improved response since presentation at ASH 2014
14 Phase II Study in Front Line AML: Conclusions Significant clinical activity in elderly patients w/ newly diagnosed AML 52% (17/33) have now achieved primary endpoint o CR = 33% (11/33) to date Majority of clinical responses occur within first two cycles Observed response rate continues to increase with longer follow-up Only one patient who has achieved clinical benefit (SD) has progressed 60-day mortality rate approximately 10% (3/33) Well tolerated in this population of elderly AML patients ( 65 years) To date 12 patients on study > 6 months, reflecting long term tolerability Data support definitive development of Pracinostat in combination with azacitidine in elderly AML patients 14
15 Proposed Phase III Study in Front Line AML Elderly (Age 60 years) Patients with Newly Diagnosed AML Unsuitable for Intensive Therapy Pracinostat + Azacitidine Placebo + Azacitidine Primary endpoint to support accelerated approval: CR Endpoint for full approval: OS ~450 patients, one-to-one randomization Estimated initiation: June
16 Global Market Opportunity in MDS and AML MDS and AML are Growing Markets with Limited Treatment Options HSCT is the only curative treatment; however, the vast majority of patients are ineligible candidates Many patients are also unfit for chemotherapy Most patients who are high-risk and/or can t tolerate intensive therapy receive an HMA (e.g. Vidaza or Dacogen ) In 2013 prior to generic entrants, combined worldwide sales of Vidaza and Dacogen exceeded $1B Pracinostat in combination with HMAs may improve treatment outcomes in a large, unmet market 2013 Epidemiology and Treatment Algorithm * # G7 Markets MDS Prevalence & AML Incidence ~ K Patients High Risk / Int-2 MDS & AML >60 Yrs ~ 50-60K Patients HMA Treated MDS & AML ~ 18-23K Patients Estimate ~30K Pracinostat Target Patients in 7 Key Markets by 2021 General & elderly population growth Increased Rx use in older patients Improved treatment options 16 * Evaluate Pharma # Decision Resources
17 ME-344: Lead Mitochondrial Inhibitor Derived from in-house isoflavone-based technology platform Targets Oxphos pathway resulting in rapid loss of cellular energy and mitochondrial instability via increased ROS Potent inhibitor of multiple human tumor cell lines, including chemotherapy-resistant ovarian cancer stem cells Solid tumor dose-escalation study complete ~ 25% (5/21) experienced progression-free survival (PFS) > 2X longer than prior anti-cancer therapy One confirmed PR in a patient with small cell lung cancer lasting > 2 years Dose limiting toxicity of Grade 3 neuropathy at 15 and 20 mg/kg Generally well tolerated at 10 mg/kg weekly 17
18 Phase Ib Trial of ME-344 Plus Topotecan First Patient Dosed in Cohort Expansion in Oct 2014 Primary Endpoint: Safety & Tolerability of ME Topotecan Patients Eligible for Topotecan Small Cell Lung, Ovarian & Cervical Cancers Confirm MTD (n=14) ME-344 (10 mg/kg weekly) + Topotecan (4 mg/m 2 day 1,8,15) Small Cell Lung Cancer (n=20) ME Topotecan Ovarian Cancer (n=20) ME Topotecan 18
19 PWT143: Highly Selective PI3K Delta Inhibitor Acquired from Pathway Therapeutics in September 2013 Expands drug development pipeline Clinically validated target in hematologic diseases Potential synergies with lead drug candidate Pracinostat Distinct chemical structure and evidence of improved pre-clinical activity compared to other PI3K delta inhibitors in development IND-enabling 2-species tox studies and scale manufacturing methods completed Expect to initiate first-in-human studies in first half of
20 Intellectual Property Pracinostat 3 issued US and 77 issued foreign patents 2 US and 8 foreign applications pending Composition of matter to May 2028 in US, Aug 2026 in EP May 2033 with up to 5 years patent term restoration in US Aug 2031 with up to 5 years Supplementary Protection Certificate in EP ME issued US and 18 issued foreign patents 3 US and 7 foreign applications pending Composition of matter to Sep 2025 in US and EP Sep 2029 with up to 4 years of patent term restoration in US Sep 2030 with up to 5 years Supplementary Protection Certificate in EP PWT143 1 issued US patent 3 US and 29 foreign applications pending Composition of matter to Jan 2031 in US, pending in EP 20
21 Financial Highlights Cash: $78.7 million (as of December 31, 2014) Debt: None Shares outstanding: 33.3 million 21
22 2015 Clinical Milestones Pracinostat Top-line data from Phase II study in front line MDS (March) Full data from Phase II study in front line MDS (June) Full data from Phase II study in front line elderly AML (June) Initiation of Phase III study in front line elderly AML (June) ME-344 Data from Phase Ib trial in small cell lung and ovarian cancers PWT143 Initiation of first-in-human study 22
23 [ NASDAQ: MEIP ] Cowen and Company Health Care Conference March 2015
[ NASDAQ: MEIP ] Cantor Fitzgerald Healthcare Conference July 8, 2015
[ NASDAQ: MEIP ] Cantor Fitzgerald Healthcare Conference July 8, 2015 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or
More information[ NASDAQ: MEIP ] August 2014
[ NASDAQ: MEIP ] August 2014 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or results may differ materially from those
More information[ NASDAQ: MEIP ] Analyst & Investor Event December 8, 2014
[ NASDAQ: MEIP ] Analyst & Investor Event December 8, 2014 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or results may
More information[ NASDAQ: MEIP ] Stifel Healthcare Conference November 15-16, 2016
[ NASDAQ: MEIP ] Stifel Healthcare Conference November 15-16, 2016 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or results
More information[ NASDAQ: MEIP ] BIO CEO & Investor Conference February 8-9, 2016
[ NASDAQ: MEIP ] BIO CEO & Investor Conference February 8-9, 2016 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or results
More informationNeedham Healthcare Conference
Needham Healthcare Conference April 4, 2017 NASDAQ: MEIP Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or results may
More information[ NASDAQ: MEIP ] Wedbush PacGrow Healthcare Conference August 16-17, 2016
[ NASDAQ: MEIP ] Wedbush PacGrow Healthcare Conference August 16-17, 2016 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events
More informationTwo-stage study designed to evaluate tolerability and efficacy of pracinostat combined with azacitidine in patients with high and very high risk MDS
Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome Two-stage study designed to evaluate tolerability
More informationCorporate Presentation
Corporate Presentation October 2017 NASDAQ: MEIP Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or results may differ materially
More informationNASDAQ: MEIP. Pioneering New Therapies for Cancer September 2017
ASDAQ: MEIP Pioneering ew Therapies for Cancer September 2017 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or results
More informationNewsMakers in the Biotech Industry
ASDAQ: MEIP ewsmakers in the Biotech Industry September 8, 2017 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or results
More information[ NASDAQ: MSHL ] Southern California Investor Conference August 29, 2011
[ NASDAQ: MSHL ] Southern California Investor Conference August 29, 2011 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events
More informationStifel Healthcare Conference
Stifel Healthcare Conference ovember 2017 ASDAQ: MEIP Forward-Looking Statements This presentation contains, and our officers and representatives may from time to time make, statements that are forward-looking
More informationCorporate Presentation
Corporate Presentation January 2018 ASDAQ: MEIP Forward-Looking Statements This presentation contains, and our officers and representatives may from time to time make, statements that are forward-looking
More informationBuilding a Leading Oncology Franchise
ASDAQ: MEIP Building a Leading Oncology Franchise 17th Annual eedham Healthcare Conference March 27, 2018 Forward-Looking Statements This presentation contains, and our officers and representatives may
More informationDisrupting the Cell Cycle to Treat AML and MDS Rodman & Renshaw Conference
CYC 682 Disrupting the Cell Cycle to Treat AML and MDS Rodman & Renshaw Conference September 2014 Disclaimer This presentation contains forward-looking statements within the meaning of the safe harbor
More informationAcute Myeloid Leukemia
Acute Myeloid Leukemia Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University Outline Molecular biology Chemotherapy and Hypomethylating agent Novel Therapy
More informationBuilding a Leading Oncology Franchise
Building a Leading Oncology Franchise January 2019 NASDAQ: MEIP Forward-Looking Statements This presentation contains, and our officers and representatives may from time to time make, statements that are
More informationThird Quarter 2018 Financial Results. November 1, 2018
Third Quarter 2018 Financial Results November 1, 2018 Agios Conference Call Participants Prepared Remarks Introduction RENEE LECK, Associate Director, Investor Relations Business Highlights & 2018 Key
More informationTARGET A BETTER NOW FORWARD-LOOKING STATEMENTS NASDAQ: IMGN. Current as of January 2018
NASDAQ: IMGN TARGET A BETTER NOW Current as of January 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward looking statements based on management's current expectations. These statements
More informationInducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy
Inducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy Company Overview, September 2018 Safe Harbor Statement This presentation contains forward-looking
More informationActinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting
December 4, 2018 Actinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting - Key highlights include near universal engraftment
More informationStifel Healthcare Conference John Scarlett, M.D. Chief Executive Officer November 19, 2014
Stifel Healthcare Conference 2014 John Scarlett, M.D. Chief Executive Officer November 19, 2014 1 forward-looking statements Except for statements of historical fact, the statements during this presentation
More informationSunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results
Investor and Media Inquiries: David Pitts Argot Partners 212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals Inc. 650-266-3717 Sunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results SOUTH
More informationMyeloid Differentiation Observed, Including Induction of CD38 in 85% of Evaluable Patients
December 10, 2017 Syros Announces Initial Clinical Data from Ongoing Phase 2 Trial of SY-1425 Showing Biological and Clinical Activity as Single Agent in Genomically Defined AML and MDS Patients Clinical
More informationCorporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC
Corporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts
More informationNovogen Limited. An emerging oncology drug developer with two clinical-stage programs NRT NVGN. April 2017
Novogen Limited An emerging oncology drug developer with two clinical-stage programs NRT April 2017 NVGN Forward-Looking Statements This presentation contains forward-looking statements within the meaning
More information(908) (908)
Contact: Robert J. Hugin Brian P. Gill Senior VP and CFO Director, PR/IR Celgene Corporation Celgene Corporation (908) 673-9102 (908) 673-9530 REVLIMID (lenalidomide) SIGNIFICANTLY DELAYS TIME TO DISEASE
More informationTransforming science into medicine
Transforming science into medicine 2 Forward-looking statements This presentation contains forward-looking statements. These statements include words like may, expects, believes, plans, scheduled, and
More informationSummary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain
Summary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain EHA 2017 ANNUAL MEETING: ABSTRACT SEARCH PAGE: https://learningcenter.ehaweb.org/eha/#!*listing=3*browseby=2*sortby=1*media=3*ce_id=1181*label=15531
More informationNeedham Healthcare Conference. April 4, 2017
Needham Healthcare Conference April 4, 2017 Forward Looking Statements This presentation and various remarks we make during this presentation contain forward-looking statements within the meaning of The
More informationCorporate Overview May 8, 2014
0 Corporate Overview May 8, 2014 NASDAQ: CRIS Forward Looking Statements This presentation contains statements about Curis future expectations, plans and prospects that constitute forward-looking statements
More informationBusiness Update & Financial Results for Q1 2018
Business Update & Financial Results for Q1 2018 May 15, 2018 Disclaimer The statements made in this presentation may include forward-looking statements regarding the future operations of ERYTECH Pharma
More informationDisrupting the Cell Cycle to Treat AML, MDS and other Cancers
CYC 682 Disrupting the Cell Cycle to Treat AML, MDS and other Cancers February 2015 Disclaimer This presentation contains forward-looking statements within the meaning of the safe harbor provisions of
More informationBuilding a Fully Integrated Biopharmaceutical Company. June 2014
Building a Fully Integrated Biopharmaceutical Company June 2014 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer January 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results
More informationFor personal use only. A new company with: a new technology platform for cancer drug development a new management team a new Board
A new company with: a new technology platform for cancer drug development a new management team a new Board Disclaimer This presentation is confidential and is not an offer or a recommendation or intended
More informationBio-Path Announces Clinical Update to Interim Analysis of Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia
Bio-Path Announces Clinical Update to Interim Analysis of Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia Interim Data Update from Phase 2 Study Demonstrates Meaningful Clinical Improvement with
More informationEnasidenib Monotherapy is Effective and Well-Tolerated in Patients with Previously Untreated Mutant-IDH2 Acute Myeloid Leukemia
Enasidenib Monotherapy is Effective and Well-Tolerated in Patients with Previously Untreated Mutant-IDH2 Acute Myeloid Leukemia Pollyea DA 1, Tallman MS 2,3, de Botton S 4,5, DiNardo CD 6, Kantarjian HM
More informationNewLink Genetics Corporation
Cantor Fitzgerald 2018 Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK October 3, 2018 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking
More informationDisclosure Slide. Research Support: Onconova Therapeutics, Celgene
Oral Rigosertib Combined with Azacitidine in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS): Effects in Treatment Naïve and Relapsed- Refractory Patients Shyamala C. Navada,
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer March 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn's actual results may
More informationForward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements, including statements related to Seattle Genetics corporate priorities, financial guidance and anticipated upcoming activities,
More informationCompany Overview. April Rewriting cancer treatment NASDAQ: EPZM
Company Overview NASDAQ: EPZM Rewriting cancer treatment Forward Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform
More informationKaryopharm Reports Second Quarter 2015 Financial Results and Highlights Recent Progress
August 10, 2015 Karyopharm Reports Second Quarter 2015 Financial Results and Highlights Recent Progress - Positive Selinexor Clinical Data Presented across Several Difficult to Treat Cancers - - Provides
More informationFull Year 2017 Financial Results. February 14, 2018
Full Year 2017 Financial Results February 14, 2018 Agios Conference Call Participants Prepared Remarks Introduction KENDRA ADAMS, Sr. Director, Investor Relations 2018 Vision & Key Milestones DAVID SCHENKEIN,
More informationEmerging Treatment Options for Myelodysplastic Syndromes
Emerging Treatment Options for Myelodysplastic Syndromes James K. Mangan, MD, PhD Assistant Professor of Clinical Medicine Abramson Cancer Center, University of Pennsylvania Please note that some of the
More informationDisclosure. Study was sponsored by Karyopharm Therapeutics No financial relationships to disclose Other disclosures:
Combination of Selinexor with High-Dose Cytarabine and Mitoxantrone for Remission Induction in Acute Myeloid Leukemia is Feasible and Tolerable A Phase I Study (NCT02573363) Amy Y. Wang, Howie Weiner,
More informationActinium Pharmaceuticals, Inc.
, Inc. Actimab-A MRD Consolidation Strategy in MRD+ AML July 10, 2018 1 Disclaimer and Safe Harbor Some of the information presented herein may contain projections or other forward-looking statements regarding
More informationSunesis Pharmaceuticals Reports Third Quarter 2014 Financial Results and Recent Highlights
Sunesis Pharmaceuticals Reports Third Quarter 2014 Financial Results and Recent Highlights November 10, 2014 7:00 AM ET Announces Submission of Letter of Intent to File MAA for Vosaroxin in Relapsed or
More informationPersonalized Therapeutics The Power of Epigenetics. Company Overview. June 2014
Personalized Therapeutics The Power of Epigenetics Company Overview June 2014 2013 Accomplishments Forward Looking Statements This presentation contains forward-looking statements that involve substantial
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer June 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results may
More informationA company developing innovative, high-impact drugs for cancer
A company developing innovative, high-impact drugs for cancer Investor Briefing March 2019 ASX: KZA NASDAQ : KZIA Twitter: @KaziaTx Forward-Looking Statements This presentation contains forward-looking
More informationEHA 2017 Abstracts: 4 Abstracts ( 1 Oral Presentation, 2 EPosters, 1 Publication)
EHA 2017 Abstracts: 4 Abstracts ( 1 Oral Presentation, 2 EPosters, 1 Publication) ORAL RIGOSERTIB COMBINED WITH AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) AND MYELODYSPLASTIC SYNDROMES (MDS):
More informationVAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients. September 2018
VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients September 2018 Forward-Looking Statements Any statements contained in this presentation that do not describe historical facts may
More informationTransforming patients lives through cellular immunotherapy. Next Generation Cellular Immunotherapy June 2017
Transforming patients lives through cellular immunotherapy Next Generation Cellular Immunotherapy June 2017 1 Overview of Cell Medica Mission: Transform the treatment of cancer with cellular immunotherapy
More informationANCO: ASCO Highlights 2018 Hematologic Malignancies
ANCO: ASCO Highlights 2018 Hematologic Malignancies Brian A. Jonas, M.D., Ph.D. UC Davis Comprehensive Cancer Center August 25, 2018 Brian Jonas, MD, PhD ANCO: ASCO Highlights 2018 Relevant financial relationships
More informationSafety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naïve Patients Aged 65 Years With Acute Myeloid Leukemia
Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naïve Patients Aged 65 Years With Acute Myeloid Leukemia Abstract 102 Wei AH, Strickland SA, Roboz GJ, Hou J-Z, Fiedler W, Lin TL,
More informationASCO Analyst & Investor Webcast. June 1, 2018
ASCO Analyst & Investor Webcast June 1, 2018 June 1, 2018 NASDAQ: BLUE Forward Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and information
More informationSmall-Cap Research. Celator Pharma (CPXX-NASDAQ)
Small-Cap Research July 21, 2014 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Celator Pharma (CPXX-NASDAQ) CPXX: New Applications revealed, Unique
More informationSafe Harbor Statement
September 2007 Safe Harbor Statement During the course of this presentation we will make forward-looking statements that involve risks and uncertainties associated with a developing pharmaceutical company.
More informationThird Quarter 2015 Earnings Call. November 9, 2015
Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements
More informationBobby W. Sandage, Jr., PhD President & Chief Executive Officer. Lazard Capital Markets 8 th Annual Healthcare Conference
Bobby W. Sandage, Jr., PhD President & Chief Executive Officer Lazard Capital Markets 8 th Annual Healthcare Conference Statements in this presentation that are not descriptions of historical facts are
More informationSmall-Cap Research. Celator Pharma (CPXX-NASDAQ)
Small-Cap Research June 24, 2015 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Celator Pharma (CPXX-NASDAQ) CPXX: Positive top line data reported for
More informationThe Changing Face of MDS: Advances in Treatment
Thank you very much again for listening to me. We are going to be talking now in terms of therapy of MDS or The Changing Face of MDS Advances in Treatment. My name is Guillermo Garcia-Manero. I am a Professor
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO Forward-Looking Statements This presentation,
More informationLION. Corporate Presentation June 2016 BIOTECHNOLOGIES. Leadership & Innovation in Oncology
LION BIOTECHNOLOGIES Leadership & Innovation in Oncology Corporate Presentation June 2016 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationPersonalized Therapy for Acute Myeloid Leukemia. Patrick Stiff MD Loyola University Medical Center
Personalized Therapy for Acute Myeloid Leukemia Patrick Stiff MD Loyola University Medical Center 708-327-3216 Major groups of Mutations in AML Targets for AML: Is this Achievable? Chronic Myeloid Leukemia:
More informationHALOZYME REPORTS SECOND QUARTER 2018 RESULTS
Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER
More informationFOR IMMEDIATE RELEASE
FOR IMMEDIATE RELEASE FOR UK MEDICAL AND TRADE MEDIA ONLY Takeda Presents Data from TOURMALINE-MM1 Study for Ixazomib, the First and Only Once-Weekly Oral Proteasome Inhibitor Studied in Phase III Clinical
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer September 2013 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results
More informationIMMUNOMEDICS, INC. November Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases November 2017 Forward-Looking Statements This presentation, in addition to historical information, contains certain
More informationCombination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS)
Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS) Shyamala C. Navada, MD 1, Guillermo Garcia-Manero, MD 2, Katherine Hearn, RN 2, Rosalie Odchimar-Reissig,
More informationNEWS RELEASE Media Contact: Megan Pace Investor Contact: Kathee Littrell Patient Inquiries: Ajanta Horan
NEWS RELEASE Media Contact: Megan Pace 650-467-7334 Investor Contact: Kathee Littrell 650-225-1034 Patient Inquiries: Ajanta Horan 650-467-1741 GENENTECH RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR
More informationNewLink Genetics Corporation
Stifel Healthcare Conference Presentation NewLink Genetics Corporation NASDAQ: NLNK November 13, 2018 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements
More informationMedia Release. Roche announces EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia
Media Release Roche announces EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia Approval is based on randomised phase III MURANO study showing that
More informationEndoxifen Clinical Update February 1, 2018
Endoxifen Clinical Update February 1, 2018 107 Spring Street Seattle, WA 98104 USA Forward-looking Statements Some of the information presented herein may contain projections or other forward-looking statements
More informationIdenix Pharmaceuticals Building a Leading Antiviral Franchise. Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston
Idenix Pharmaceuticals Building a Leading Antiviral Franchise Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston Safe Harbor This presentation includes forward-looking statements
More informationStrengthening the Foundation of Cancer Care
www.hanabiosciences.com NASDAQ HNAB Strengthening the Foundation of Cancer Care Forward Looking Statements This material contains forward looking statements as defined by the Private Securities Litigation
More informationREWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES
REWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES May 18, 2017 Molecularly Defined Solid Tumor Program Update FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations,
More informationJefferies 2015 Global Healthcare Conference June 1, 2015
Jefferies 2015 Global Healthcare Conference June 1, 2015 Page 0 Acceleron Forward-Looking Statements This presentation contains forward-looking statements. Forward-looking statements are neither historical
More informationJefferies 2016 Healthcare Conference. Reid Huber, PhD Chief Scientific Officer
Jefferies 2016 Healthcare Conference Reid Huber, PhD Chief Scientific Officer June 8, 2016 Forward-looking Statements Except for the historical information set forth herein, the matters set forth in this
More informationAcquisition of Tolero Pharmaceuticals, Inc. December 21, 2016 Sumitomo Dainippon Pharma Co., Ltd.
Acquisition of Tolero Pharmaceuticals, Inc. December 21, 2016 Sumitomo Dainippon Pharma Co., Ltd. Acquisition of Tolero Pharmaceuticals, Inc. Significance of the Acquisition Acquire attractive compounds
More informationCREDIT DESIGNATION STATEMENT
CME Information LEARNING OBJECTIVES Recall the dose-limiting toxicity and preliminary clinical response results with 14- and 21-day extended treatment schedules of daily oral azacitidine. Apply new research
More informationAnnounce Expected Initiation of an Investigator-Initiated, Randomized, Phase 2, Multicenter Trial of Ficlatuzumab and Cetuximab in HNSCC in 2H 2017
AVEO Oncology and Biodesix Announce Results from Two Investigator-Sponsored Phase 1 Studies of HGF Targeted Antibody Ficlatuzumab at the 2017 ASCO Annual Meeting Announce Expected Initiation of an Investigator-Initiated,
More informationCorporate Presentation. October 2017
AEPP Breakthrough technology for women s cancers Corporate Presentation October 2017 Oncolix 2017 1 Safe Harbor Certain of the statements and the projections set forth in this presentation constitute forward-looking
More informationMedia Release. Basel, 12 December 2017
Media Release Basel, 12 December 2017 Roche announces phase III data showing Venclexta/Venclyxto plus MabThera/Rituxan reduced the risk of disease progression or death by 83% compared to a standard of
More information9M RESULTS 2014 CONFERENCE CALL DR. MATTHIAS SCHROFF, CEO
9M RESULTS 2014 CONFERENCE CALL DR. MATTHIAS SCHROFF, CEO BERLIN, 13 NOVEMBER, 2014 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future or future developments,
More informationCorporate Presentation. December, 2018
Corporate Presentation December, 2018 Forward Looking Statement This presentation contains estimates, projections and other forward-looking statements, concerning, among other things: our research and
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2015 Global Healthcare Conference Peter P. Pfreundschuh, VP Finance and CFO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2015 Global Healthcare Conference Peter P. Pfreundschuh, VP Finance and CFO Forward-Looking Statements This
More informationCorporate Presentation September Nasdaq: ADXS
Corporate Presentation September 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements regarding the ability and
More informationDepartment of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 2 Sunesis Pharmaceuticals, Inc, South San Francisco
Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) Naval Daver 1, Hagop Kantarjian 1, Guillermo
More informationMOLOGEN AG. Pioneering Immune Therapy. Annual Results Analysts Call March 25, 2014
Pioneering Immune Therapy Annual Results 2013 Analysts Call March 25, 2014 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future or future developments,
More informationDeveloping Targeted Therapeutics. Providing Safe and Effective New Treatment Options for Patients Most Likely to Respond
Developing Targeted Therapeutics Providing Safe and Effective New Treatment Options for Patients Most Likely to Respond Forward-Looking Statements Certain statements in this presentation are forward-looking
More informationSumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company)
December 21, 2016 Sumitomo Dainippon Pharma Co., Ltd. Sumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company) Sumitomo Dainippon Pharma Co., Ltd. (Head office: Osaka,
More informationOncology Therapeutics without Compromise APRIL 2011
Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 3Q 2018 EARNINGS PRESENTATION NOVEMBER 2018 1 Forward-looking statements disclosure This presentation
More informationPharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human BTK- Inhibitor PCI-32765
Contact: Ramses Erdtmann Vice President of Finance Phone: 408-215-3325 Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human BTK- Inhibitor PCI-32765 Company to Host
More informationCorporate Presentation
Corporate Presentation Leerink Global Healthcare Conference February 14 th -15 th, 2018 C O N F I D E N T I A L a n d P R O P R I E T A R Y Forward Looking Statements / Safe Harbor This presentation contains
More information